Abnormality of adipokines and endothelial dysfunction in Mexican obese adolescents with insulin resistance

Segura, Maria del Carmen Ortiz; Navarro, Blanca E. del Río; Espino, Benjamín Antonio Rodríguez; Marchat, Laurence A.; Sánchez‐Muñoz, Fausto; Villafaña, Santiago; Hong, Enrique; Meza-Cuenca, Fabián; Mailloux-Salinas, Patrick; Bolaños-Jiménez, Francisco; Zambrano, Elena; Arredondo-López, Abel Armando; Bravo, Gerardo Ferrando; Huang, Fengyang

doi:10.1080/07435800.2017.1294601

Cited by 10 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced levels of Ad (in particular of its HMW oligomers) have been reported in obese children, compared to normal weight control subjects [63,64,65,66,67]. It has also been reported that male children with persistent obesity have lower Ad levels than those with transient obesity; therefore, low levels of Ad could be a predictor of persistent obesity among boys [68].…”

Section: Adiponectin Obesity and Metabolic Syndromementioning

confidence: 99%

“…Plasma Ad levels are inversely correlated with waist circumference, a marker of abdominal obesity [52]; moreover, weight and waist circumference-to-height ratio are independently associated with plasma Ad concentrations [64]. Other authors demonstrated that waist circumference is an independent determinant of plasma Ad concentration, suggesting that visceral adipose tissue has a central role in reducing circulating levels of Ad [67]. Moreover, high leptin to Ad ratio has been associated with BMI Z-score gain and waist to height ratio gain in non-obese children [68].…”

Section: Adiponectin Obesity and Metabolic Syndromementioning

confidence: 99%

See 1 more Smart Citation

Adiponectin and Cardiovascular Risk. From Pathophysiology to Clinic: Focus on Children and Adolescents

Orlando

Nava

Giussani³

et al. 2019

IJMS

View full text Add to dashboard Cite

Adiponectin (Ad) is a cytokine produced by adipocytes that acts on specific receptors of several tissues through autocrine, paracrine, and endocrine signaling mechanisms. Ad is involved in the regulation of cell survival, cell growth, and apoptosis. Furthermore, Ad plays an important pathophysiological role in metabolic activities by acting on peripheral tissues involved in glucose and lipid metabolism such as skeletal muscle, and the liver. Adiponectin has anti-inflammatory, anti-atherogenic, and insulin-sensitizing effects. For this reason, low levels of Ad are associated with the development of cardiovascular complications of obesity in adulthood. Numerous studies have shown that, even in children and adolescents, Ad is associated with risk factors for cardiovascular diseases. In obese children, reduced levels of Ad have been reported and Ad plasma levels are inversely related with abdominal obesity. Moreover, lower Ad concentrations are associated with the development of metabolic syndrome, insulin resistance and hypertension in pediatric subjects. In addition to a higher prevalence of cardiovascular risk factors, plasma values of Ad are also inversely associated with early organ damage, such as an increase in carotid intima-media thickness. It has been suggested that low Ad levels in childhood might predict the development of atherosclerosis in adulthood, suggesting the possibility of using Ad to stratify cardiovascular risk in obese children. Some evidence suggests that lifestyle modification may increase Ad plasma levels. The aim of this review is to summarize the evidence on the relationship between Ad, obesity, metabolic alterations and hypertension in children and adolescents, and to address the possibility that Ad represents an early marker of cardiovascular risk in pediatric subjects. Furthermore, the effects of non-pharmacological treatment (weight loss and physical activity) on Ad levels are considered.

show abstract

Section: Adiponectin Obesity and Metabolic Syndromementioning

confidence: 99%

Section: Adiponectin Obesity and Metabolic Syndromementioning

confidence: 99%

Adiponectin and Cardiovascular Risk. From Pathophysiology to Clinic: Focus on Children and Adolescents

Orlando

Nava

Giussani³

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…The above-described properties of adiponectin were proved in both experimental and clinical studies [17,[48][49][50]. Ortiz Segura MDC et al indicated that the adiponectin concentrations were lower and soluble ICAM-1 levels as markers of endothelium dysfunction were increased in Mexican obese adolescents with insulin resistance compared to those without insulin resistance and in the controls [17]. The results of the research conducted on rat models revealed that the implementation of a high-fat diet leads to continuously increasing of pro-inflammatory cytokines, and decreasing of anti-inflammatory adiponectin levels with the first effects observed after six weeks, while NO levels were decreased at six weeks and lipid peroxidation increased in twelve weeks, which in consequence induced an increase in systolic blood pressure [48].…”

Section: Adiponectin Obesity and Insulin Resistance -When The Vicioumentioning

confidence: 95%

Section: Adiponectin Obesity and Insulin Resistance -When The Vicioumentioning

confidence: 97%

“…Among all secreted molecules, adiponectin, also known as adipocyte complement-related protein of 30 kDa (Acrp30), AdipoQ, apM1, and gelatin binding protein of 28 kD (GBP-28), structurally belonging to C1q/TNF protein family, is one of the most extensively investigated novel cytokine and promising therapeutic target in obesity-related diseases [15,16]. The results of recent years' studies have revealed the link between anti-and proinflammatory adipokines' imbalance in obesity-induced insulin resistance in adipose tissue, and endothelial dysfunction, vascular remodelling as well as have demonstrated the novel pathways involved in the pathogenesis of atherosclerosis development [17][18][19]. What is interesting, but not widely known, chronic insulin resistance state has been strengthened by epidemiological and experimental studies as independent factor increasing the risk of cardiovascular disorders [20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adiponectin as novel biomarker of endothelial dysfunction in insulin resistance and obesity – a narrative review

Szydełko

Trojanowska

Dąbrowska

et al. 2020

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Obesity is a chronic fatal disease with still growing incidence among children, adolescents, and adults worldwide. The subclinical inflammatory process together with hipoadiponectinemia may lead to the development of various comorbidities, including cardiovascular complications. That is why, the relationship between adipose tissue activity, obesity, insulin resistance, and endothelial function is in high interest and an object of extensively studies. Aim of the study: This article summarizes the current knowledge on the anti-atherogenic effects of adiponectin and its properties to improve endothelial function in obesity-related insulin resistance. Description of knowledge: Adiponectin, an adipose tissue-derived pleiotropic hormone with anti-inflammatory, anti-atherogenic, anti-diabetic, and insulin-sensitizing actions, is not only engaged in modulation of type 2 diabetes mellitus, hypertension or coronary artery disease, but the latest researches highlight its role in improving vascular wall integrity. It affects complex signaling pathways in endothelial cells and influence inflammatory responses in the subendothelial space. Pre-clinical and clinical studies suggest that agents leading to increase in adiponectin levels, simultaneously contribute to decrease insulin resistance, and improve endothelial dysfunction. Conclusions: Adiponectin may be a predictive factor of endothelial dysfunctionality and vascular remodeling development in the group of patients with overweight, obesity, and insulin resistance. Discovering pharmacological agents and non-pharmacological interventions that increase the level of circulating adiponectin will become novel and innovative therapeutic strategy to ameliorate obesity-related comorbidities. Therefore, further studies are required to determine the exact role of adiponectin in the pathogenesis of metabolic diseases.

show abstract

Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

Delgado

Roffe-Vazquez

Gonzalez‐Gil

et al. 2020

Journal of Diabetes Research

View full text Add to dashboard Cite

The prevalence of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) has increased in the pediatric population. Irisin, an adipomyokine, is involved in white adipose tissue browning, energy expenditure, insulin sensitivity, and anti-inflammatory pathways. Data on the associations among circulating irisin levels, soluble cell adhesion molecules (sCAMs), and inflammatory cytokines is scarce in children and adolescents with MetS and T2DM. Subjects aged 6-16 years were grouped into T2DM, MetS, and healthy controls. Serum irisin levels were significantly lower in the MetS (6.6 [2.8-18.0] ng/mL) and T2DM (6.8 [2.2-23.2] ng/mL) groups compared with controls (30.3 [24.6-57.1] ng/mL). Negative correlations between irisin and the BMI percentile (R=−0.358), WC percentile (R=−0.308), and triglycerides (R=−0.284) were identified, while positive associations with TC (R=0.287), HDL-c (R=0.488), and LDL-c (R=0.414) were observed. Significant negative correlations were found between irisin and sNCAM (R=−0.382), sICAM-2 (R=−0.300), sVCAM-1 (R=−0.292), MCP-1 (R=−0.308), and IFN-α2 (R=−0.406). Of note, lower concentrations of most sCAMs (sICAM-1, sPSGL-1, sP-selectin, sEpCAM, sICAM-2, sALCAM, sPECAM-1, sCD44, sVCAM-1, sICAM-3, sL-selectin, and sNCAM) were shown in T2DM subjects compared with MetS patients. Lower irisin levels induce a lack of inhibition of oxidative stress and inflammation. In T2DM, higher ROS, AGEs, glucotoxicity, and inflammation trigger endothelial cell apoptosis, which downregulates the sCAM expression as a compensatory mechanism to prevent further vascular damage. In opposition, in subjects with MetS that have not yet developed T2DM and its accompanying stressors, the upregulation of the sCAM expression is ensued.

show abstract

Abnormality of adipokines and endothelial dysfunction in Mexican obese adolescents with insulin resistance

Cited by 10 publications

References 31 publications

Adiponectin and Cardiovascular Risk. From Pathophysiology to Clinic: Focus on Children and Adolescents

Adiponectin and Cardiovascular Risk. From Pathophysiology to Clinic: Focus on Children and Adolescents

Adiponectin as novel biomarker of endothelial dysfunction in insulin resistance and obesity – a narrative review

Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

Contact Info

Product

Resources

About